Question explored with the scientific record
Are statins a net good
The short version: statins clearly help people who already have heart disease or have just had a heart attack, but for healthy people the benefit is smaller and the harms are real.
For people who have already had a heart attack or stroke, the evidence is strong. Intensive statin therapy cut deaths from about 4.6 in 100 to 3.5 in 100 over two years in people with recent acute coronary syndrome [1]. In people with stable heart disease, intensive therapy did not reduce deaths at all, though it did cut major cardiovascular events and heart failure hospitalizations [1]. A large randomized trial in 20,536 high-risk people found simvastatin cut vascular deaths by about 17% and major vascular events by about 25% over five years, without raising cancer or non-vascular deaths [7].
For healthy people without heart disease, the picture is murkier. A 2022 cohort of 12,574 men found the lowest death risk at a non-HDL cholesterol around 142-144 mg/dL, with higher death rates both below and above that range [2]. That suggests pushing cholesterol very low may not be harmless. The JUPITER trial in people with elevated inflammation but normal LDL showed rosuvastatin cut major events, but it also raised new diabetes risk by about 25% [6]. A meta-analysis of 236,864 people found statin use raised new-onset diabetes risk by about 61% [8]. High-intensity statins raise diabetes risk more than moderate doses [5].
The harms are not trivial. Muscle symptoms are common: one review notes up to 60% of current users report them, though randomized trials put the rate at 1.5-5% [9]. Intensive therapy tripled liver enzyme elevations [1]. Statin-associated muscle damage can be severe, with 3,339 rhabdomyolysis cases reported to the FDA from 1990-2002 [10].
| Population | Death benefit | Diabetes risk |
|---|---|---|
| Recent heart attack | 4.6% to 3.5% over 2 yrs [1] | Higher with intensive dose [5] |
| Stable heart disease | None [1] | Higher with intensive dose [5] |
| Healthy men (primary prevention) | U-shaped; lowest risk at ~143 mg/dL [2] | ~61% higher odds [8] |
The evidence is dominated by industry-funded trials and observational studies with residual confounding [3, 4]. The most informative comparison, healthy people on statins versus healthy people never on statins over decades, has not been run. The diabetes risk is real and dose-dependent. The muscle harm is real and undercounted in trials that exclude intolerant patients [9].
My call: statins are a net good for people with established heart disease or recent heart attack, but for healthy people the benefit is modest and the diabetes and muscle harms are real. Confidence: moderate.
Sources used 10
-
Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials
Intensive statin therapy reduces all-cause mortality in patients with recent acute coronary syndromes but not in patients with stable coronary heart disease, while reducing MACE and heart failure admissions in both groups.
DOI: 10.1136/hrt.2006.112508 -
U-Shaped Relationship of Non-HDL Cholesterol With All-Cause and Cardiovascular Mortality in Men Without Statin Therapy
Non-HDL-C demonstrated a U-shaped relationship with all-cause and cardiovascular mortality in 12,574 US men without statin therapy, with lowest mortality risk at approximately 142-144 mg/dl.
DOI: 10.3389/fcvm.2022.903481 -
Influence of Statin Therapy on the Incidence of Cardiovascular Events, Cancer, and All-Cause Mortality in People Living With HIV: A Meta-Analysis
A meta-analysis of 12 cohort studies involving 162,252 people living with HIV found statin use associated with reduced all-cause mortality and cancer risk, but no significant association with cardiovascular events.
DOI: 10.3389/fmed.2021.769740 -
Underutilization of Statin Therapy for Secondary Prevention of Cardiovascular Disease Among Older Adults
Among older AARP Medicare Supplement insureds with established CVD, high-intensity statin use was low (20% of males, 12% of females), and lower-intensity or no statins were associated with higher adjusted all-cause mortality; statins remained underutilized, especially in women.
DOI: 10.1089/pop.2018.0051 -
Different diabetogenic effect of statins according to intensity and dose in patients with acute myocardial infarction: a nationwide cohort study
This nationwide cohort study investigates the differential diabetogenic effects of statins based on their intensity and dose in patients with acute myocardial infarction, revealing that high-intensity statin therapy is associated with a higher incidence of new-onset diabetes mel…
DOI: 10.1038/s41598-024-67585-7 -
Balancing the cardiometabolic benefits and risks of statins
A Lancet commentary assessing the balance between the cardiovascular benefits and the diabetogenic risk of statins, especially rosuvastatin in the JUPITER primary-prevention trial, and arguing for risk-aware prescribing, monitoring, and further mechanistic and population-specifi…
DOI: 10.1016/S0140-6736(12)61301-4 -
The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]
A large, randomized placebo-controlled trial (Heart Protection Study) in 20,536 high-risk UK adults shows that lowering LDL cholesterol with simvastatin 40 mg daily for about 5 years reduces vascular mortality by ~17% and major vascular events by ~25% without increasing non-vasc…
DOI: 10.1186/1741-7015-3-6 -
Statins and New-Onset Diabetes in Cardiovascular and Kidney Disease Cohorts: A Meta-Analysis
A meta-analysis of 11 studies (236,864 subjects) found statin use was associated with a small but statistically significant increased risk of new-onset diabetes mellitus (fixed-effects OR 1.61, 95% CI 1.55-1.68; p < 0.001).
DOI: 10.1159/000485196 -
Statin Toxicity
A comprehensive, mechanistic review of statin toxicity with a focus on statin-associated muscle symptoms (SAMS), detailing the mevalonate pathway effects, mitochondrial and calcium signaling perturbations, genetic factors, clinical presentations, prevalence, potential biomarkers…
DOI: 10.1161/circresaha.118.312782 -
Statin-Associated Myopathy
Statins are associated with skeletal muscle complaints including myositis, rhabdomyolysis, myalgia, weakness, and cramps; the FDA MEDWATCH database lists 3339 cases of statin-associated rhabdomyolysis from 1990 to 2002, with cerivastatin most commonly implicated, and risk is exa…
DOI: 10.1001/jama.289.13.1681